National Network Genomic Medicine Lung Cancer, Germany

Last updated: July 3, 2023
Sponsor: Prof. Dr. Juergen Wolf
Overall Status: Active - Recruiting

Phase

N/A

Condition

Carcinoma

Treatment

observational, non-interventional

Clinical Study ID

NCT05934032
NNGM0418
  • Ages > 18
  • All Genders

Study Summary

Registry of the national Network Genomic Medicine Lung Cancer (nNGM), linking data on molecular diagnostics, clinical characteristics, treatment patterns and outcomes of subjects with non-small cell lung cancer (NSCLC) from 23 specialized cancer centres and more than 400 general hospitals and oncological practices in Germany

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years
  • Histologically confirmed, locally advanced or metastatic NSCLC (Union forInternational Cancer Control [UICC] stage IIIb/IV; non-resectable NSCLC)
  • From 07/2023: histologically confirmed NSCLC stage Ib, II, III (UICC)

Exclusion

Exclusion Criteria:

  • Missing written informed consent

Study Design

Total Participants: 30000
Treatment Group(s): 1
Primary Treatment: observational, non-interventional
Phase:
Study Start date:
April 01, 2018
Estimated Completion Date:
December 31, 2030

Study Description

Within the national Network Genomic Medicine Lung Cancer (nNGM), comprehensive molecular diagnostics and treatment recommendations are provided by 23 certified cancer centres according to standardized procedures for patients with non-resectable NSCLC. More than 400 network partners across Germany (including hospitals and oncological practices) report data on subsequent treatment and outcomes to the nNGM registry. Clinical outcomes are continuously evaluated through analysis of data collected in a decentralized registry. The nNGM registry records the patient journey and course of the disease from first histologically confirmed diagnosis to death or loss to follow-up and comprises detailed data on demographic and clinical characteristics, molecular diagnostics (including comprehensive biomarker testing results), treatments (targeted therapy, immunotherapy, chemotherapy, radiotherapy, best supportive care) and outcomes (overall survival, response, disease progression, time to next treatment). Patients have been actively involved throughout all stages of the design and running of the network and its registry.

Connect with a study center

  • University Hospital Cologne

    Cologne,
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.